Increased Level of Screening Drives Cancer IVD Sector

By Labmedica staff writers
Posted on 30 Jun 2008

The increased level of cancer screening, a public health priority as well as a healthcare cost priority, continues to drive basic testing techniques such as fecal occult blood testing. Advances in pharmacodiagnostic technologies, genetic tests, and molecular tests, which determine tumor growth pathways in the evaluation of patients at risk, offer the potential to open new market niches.

The emergence of a new approach, which views cancer as a chronic disease has also been a boon for IVD developers. With advances in early screening and improved therapeutics, there is more need for cancer management and monitoring tests.

A Report Buyer (London, UK) report showed that the world market for in-vitro diagnostic (IVD) cancer tests is growing at nearly 11% annually and could reach US$8 billion by the end of 2012.

Report Buyer is a UK-based independent online store supplying business information. The website now carries over 70,000 business information products, including market reports, studies, books, and events.

Related Links:
Report Buyer